Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311997 | 0.94 | CETP (0.49) | CETPNR4A2MAOBFFAR1 | |
| SCHEMBL6304795 | 0.94 | CETP (0.49) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL7081962 | 0.89 | CETP (0.51) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL6307720 | 0.88 | CETP (0.64) | CETPNR4A2 | |
| SCHEMBL6306920 | 0.88 | CETP (0.46) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL6307697 | 0.87 | CETP (0.47) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL6304798 | 0.86 | CETP (0.47) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL6311873 | 0.86 | CETP (0.49) | CETP | |
| SCHEMBL6304804 | 0.86 | CETP (0.46) | CETPNR4A2MAOBMRGPRX4MAPT | |
| SCHEMBL6311803 | 0.85 | CETP (0.55) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861561-B2 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | claimed |
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-12-04 | — | — | US | claimed |
| US-6482862-B1 | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, MTTP | CETP 1/4885NR4A2 1830/4885MAOB 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.